HK1165287A1 - Influenza vaccine regimens for pandemic-associated strains - Google Patents

Influenza vaccine regimens for pandemic-associated strains

Info

Publication number
HK1165287A1
HK1165287A1 HK12105965.6A HK12105965A HK1165287A1 HK 1165287 A1 HK1165287 A1 HK 1165287A1 HK 12105965 A HK12105965 A HK 12105965A HK 1165287 A1 HK1165287 A1 HK 1165287A1
Authority
HK
Hong Kong
Prior art keywords
pandemic
influenza vaccine
vaccine regimens
associated strains
strains
Prior art date
Application number
HK12105965.6A
Other languages
English (en)
Chinese (zh)
Inventor
Nicola Groth
Elena Fragapane
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42111679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1165287(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1165287A1 publication Critical patent/HK1165287A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
HK12105965.6A 2009-02-10 2012-06-19 Influenza vaccine regimens for pandemic-associated strains HK1165287A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20737109P 2009-02-10 2009-02-10
PCT/IB2010/000302 WO2010092476A1 (en) 2009-02-10 2010-02-10 Influenza vaccine regimens for pandemic-associated strains

Publications (1)

Publication Number Publication Date
HK1165287A1 true HK1165287A1 (en) 2012-10-05

Family

ID=42111679

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12105965.6A HK1165287A1 (en) 2009-02-10 2012-06-19 Influenza vaccine regimens for pandemic-associated strains
HK16104343.8A HK1216498A1 (zh) 2009-02-10 2016-04-15 用於大流行相關毒株的流感疫苗方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16104343.8A HK1216498A1 (zh) 2009-02-10 2016-04-15 用於大流行相關毒株的流感疫苗方案

Country Status (12)

Country Link
US (2) US20120093859A1 (ko)
EP (2) EP2942062A1 (ko)
JP (2) JP5778039B2 (ko)
KR (1) KR20110132373A (ko)
CN (1) CN102438651A (ko)
AU (1) AU2010212547B2 (ko)
CA (1) CA2752039A1 (ko)
EA (1) EA201171032A1 (ko)
ES (1) ES2552383T3 (ko)
HK (2) HK1165287A1 (ko)
SI (1) SI2396030T1 (ko)
WO (1) WO2010092476A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2601969T3 (en) 2006-09-29 2016-04-18 Takeda Vaccines Inc Norovirus vaccine formulations
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
EA201171032A1 (ru) * 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
KR20140006963A (ko) 2011-02-25 2014-01-16 노파르티스 아게 외래 내부 양성 대조군
PL3299030T3 (pl) 2011-07-11 2022-12-05 Takeda Vaccines, Inc. Pozajelitowe preparaty szczepionek przeciw norowirusowi
WO2013075266A1 (en) * 2011-11-23 2013-05-30 Vacdiagn Biotechnology Co., Ltd. Immune methods against influenza viruses and combinatorial vaccines thereof
RU2599496C2 (ru) * 2012-03-06 2016-10-10 Круселл Холланд Б.В. Улучшенная вакцинация против гриппа
AU2013361781B2 (en) 2012-12-17 2017-06-29 Eurocine Vaccines Ab Intranasal vaccination dosage regimen
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
KR102632419B1 (ko) 2016-12-23 2024-01-31 인터벳 인터내셔널 비.브이. 돼지용 조합 백신
CN107469075B (zh) * 2017-08-23 2020-05-05 江苏金迪克生物技术有限公司 一种高剂量四价流感疫苗组合物
WO2023118553A1 (en) * 2021-12-24 2023-06-29 Intervet International B.V. Stable emulsions of antigens

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
NZ508013A (en) 1998-05-07 2003-08-29 Corixa Corp Adjuvant composition for use with an antigen in a vaccine composition
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
DE122008000061I1 (de) 1999-04-06 2009-02-12 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie
DE60033284T3 (de) 1999-07-14 2014-10-30 Icahn School Of Medicine At Mount Sinai In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
ATE376825T1 (de) 1999-09-24 2007-11-15 Glaxosmithkline Biolog Sa Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
KR100797547B1 (ko) 2000-03-03 2008-01-24 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
IL152426A (en) 2000-04-28 2011-07-31 St Jude Childrens Res Hospital A DNA transfection system to form an infectious negative-strand RNA virus
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
WO2002074336A2 (en) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
JP5393978B2 (ja) 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
KR20070060049A (ko) 2004-05-20 2007-06-12 아이디 바이오메디칼 코포레이션 인플루엔자 백신의 제조방법
ES2386272T3 (es) 2004-09-09 2012-08-16 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados a las vacunas antigripales
ATE547511T1 (de) 2004-12-23 2012-03-15 Medimmune Llc Nichttumorbildende mdck-zellinie zur vermehrung von viren
BRPI0518568A2 (pt) 2004-12-24 2008-11-25 Solvay Pharm Bv mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
US20090028903A1 (en) 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
PT1861120T (pt) 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
AU2006310338A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adminstration routes for priming/boosting with influenza vaccines
NZ594482A (en) * 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
US20080014217A1 (en) 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
KR20090057015A (ko) 2006-09-11 2009-06-03 노파르티스 아게 난을 사용하지 않는 인플루엔자 바이러스 백신의 제조
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
US8668904B2 (en) 2007-12-06 2014-03-11 Glaxosmithkline Biologicals S.A. Influenza composition
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
EA201171032A1 (ru) * 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами

Also Published As

Publication number Publication date
SI2396030T1 (sl) 2015-12-31
US20120093859A1 (en) 2012-04-19
EA201171032A1 (ru) 2012-02-28
HK1216498A1 (zh) 2016-11-18
JP2012517415A (ja) 2012-08-02
CA2752039A1 (en) 2010-08-19
AU2010212547A1 (en) 2011-09-01
JP2015163647A (ja) 2015-09-10
EP2942062A1 (en) 2015-11-11
AU2010212547B2 (en) 2015-03-12
ES2552383T3 (es) 2015-11-27
US20190142929A1 (en) 2019-05-16
WO2010092476A1 (en) 2010-08-19
EP2396030A1 (en) 2011-12-21
EP2396030B1 (en) 2015-08-12
JP5778039B2 (ja) 2015-09-16
KR20110132373A (ko) 2011-12-07
CN102438651A (zh) 2012-05-02

Similar Documents

Publication Publication Date Title
HK1216498A1 (zh) 用於大流行相關毒株的流感疫苗方案
IL217008A0 (en) Vaccine
GB0905570D0 (en) Combined vaccines
GB0810305D0 (en) Influenza vaccination
IL224022B (en) Thermally stable influenza vaccine
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
PL2396032T3 (pl) Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
ZA201300395B (en) Influenza vaccine
IL222228A0 (en) Hiv vaccine
GB201006165D0 (en) Vaccine
GB0918679D0 (en) Influenza vaccine
ZA201100962B (en) Influenza vaccines
GB0907935D0 (en) Vaccines
IL216102A0 (en) Combined measles-malaria vaccine
PL2482845T3 (pl) Nowa kompozycja szczepionki przeciw grypie
GB201000522D0 (en) Vaccine
GB201014965D0 (en) Vaccine
EP2424879A4 (en) INFLUENZA VACCINE
IL217194A0 (en) Vaccine
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
EP2240199A4 (en) INFLUENZA VACCINES
ZA201302154B (en) Vaccine
ZA201107971B (en) Combined measles-malaria vaccine
GB0914545D0 (en) Vaccine